Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: Efficacy and safety results from a large mono-institutional analysis

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Scartozzi, Mario ^a   Baroni, Gianluca Svegliati ^a   Faloppi, Luca ^a   Paolo, Marzia Di Pietro ^b   Pierantoni, Chiara ^a   Candelari, Roberto ^c   Berardi, Rossana ^a   Antognoli, Stefania ^a   Mincarelli, Cinzia ^c   Risaliti, Andrea ^a   Marmorale, Cristina ^a   Antico, Ettore ^c   Benedetti, Antonio ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Profili   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IODINATED POPPYSEED OIL; RADIOACTIVE MICROSPHERE; ETHIODIZED OIL; MICROSPHERE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; KAPLAN MEIER METHOD; LIVER TUMOR; METHODOLOGY; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICROSPHERES; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 78650053092     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-164     Document Type: Article

References (19)

1. Global cancer statistics, 2002. DM Parkin F Bray J Ferlay, et al. Ca Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
2. Epidemiology, risk factors and natural history of hepatocellular carcinoma. G Montalto M Cervello L Giannitrapani, et al. Ann N Y Acad Sci 2002 963 13 20 10.1111/j.1749-6632.2002.tb04090.x 12095924
3. Update treatment approach to hepatocellular carcinoma. JM Llovet, J Gastroenterol 2005 40 225 235 10.1007/s00535-005-1566-3 15830281
4. Small hepatocellular carcinoma in cirrhosis: randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. R Lencioni HP Allagaier D Cioni, et al. Radiology 2003 228 235 240 10.1148/radiol.2281020718 12759473
5. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 cm or less. S Lin C Lin C Lin, et al. Gastroenterology 2004 127 1714 1723 10.1053/j.gastro.2004.09.003 15578509
6. Chemotherapy in hepatocellular carcinoma. S Okada, Hepatogastroenterology 1998 45 suppl 3 1259 1263 9730385
7. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. GK Abou-Alfa L Schwartz S Ricci, et al. J Clin Oncol 2006 24 4293 4300 10.1200/JCO.2005.01.3441 16908937
8. SHARP Investigators. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a phase III randomized placebo-controlled trial. J Llovet S Ricci V Mazzaferro, et al. J Clin Oncol 2007 LBA1
9. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JM Llovet AM Di Bisceglie J Bruix, et al. J Nat Cancer Inst 2008 100 698 711 10.1093/jnci/djn134 18477802
10. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, N Engl J Med 1995 332 1256 61 10.1056/ NEJM199505113321903 7708069
11. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. J Bruix JM Llovet A Castells, et al. Hepatology 1998 27 1578 83 10.1002/hep.510270617 9620330
12. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. G Pelletier M Ducreux F Gay, et al. J Hepatol 1998 29 129 34 10.1016/S0168-8278(98)80187-6 9696501
13. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. C Camm F Schepis A Orlando, et al. Radiology 2002 224 47 54 12091661
14. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. JM Llovet J Bruix, Hepatology 2003 37 429 42 10.1053/jhep.2003.50047 12540794
15. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized trial. JM Llovet MI Real X Montana, et al. Lancet 2002 359 1734 39 10.1016/S0140-6736(02) 08649-X 12049862
16. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. CM Lo H Ngan WK Tso, et al. Hepatology 2002 35 1164 71 10.1053/jhep.2002.33156 11981766
17. Transarterial chemioembolizzation for hepatocellular carcinoma with drug-eluting microspheres: preliminary result from an italian multi center study. M Grosso C Vignali P Quaretti, et al. Cardiovasc Intervent Radiol 2008 31 1141 1149 10.1007/s00270-008-9409-2 18696150
18. Drug eluting beads versus conventional TACE for unresectable hepatocellular carcinoma: survival benefits and safety. R Dhanasekaran DA Kooby CA Staley, et al. ASCO Annual Metting Abstrats 2009
19. A randomized phase II trial of drug eluting bead in the treatment o hepatocellular carcinoma by transcatheter arterial chemoembolization. R Lencioni K Malagari T Vogl, et al. ASCO Annual Metting Abstrats 2009